rxstatShortages › Efavirenz

Efavirenz shortage status

Partial shortage

Source: Health Canada shortage reports · Updated Jul 9, 2026

Some Efavirenz products are in shortage in Canada (1 of 6 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
Products affected
1 / 6
In shortage since
May 14, 2025
Reports on file
13
Talk to your pharmacist. Pharmacists can often substitute another manufacturer's version, a different strength, or (in most provinces) adapt or renew a prescription on the spot. Your free provincial health line is 811.

Reports by product

Active shortage
TEVA-EFAVIRENZ
600MG · TABLET · TEVA CANADA LIMITED
DIN 02389762 · since May 14, 2025, no end estimate · Disruption of the manufacture of the drug.
Resolved
JAMP-EFAVIRENZ
600MG · TABLET · JAMP PHARMA CORPORATION
DIN 02458233 · ended Jul 31, 2025 · Disruption of the manufacture of the drug.
Discontinued
TEVA-EFAVIRENZ
600MG · TABLET · TEVA CANADA LIMITED
DIN 02389762
Resolved
TEVA-EFAVIRENZ
600MG · TABLET · TEVA CANADA LIMITED
DIN 02389762 · ended Apr 7, 2025 · Disruption of the manufacture of the drug.
Resolved
TEVA-EFAVIRENZ
600MG · TABLET · TEVA CANADA LIMITED
DIN 02389762 · ended Jul 5, 2023 · Disruption of the manufacture of the drug.
Resolved
TEVA-EFAVIRENZ
600MG · TABLET · TEVA CANADA LIMITED
DIN 02389762 · ended Jul 5, 2023 · Disruption of the manufacture of the drug.
Discontinued
SUSTIVA 200MG
200MG · CAPSULE · BRISTOL-MYERS SQUIBB CANADA
DIN 02239888
Discontinued
SUSTIVA 50MG
50MG · CAPSULE · BRISTOL-MYERS SQUIBB CANADA
DIN 02239886
Discontinued
SUSTIVA TABLETS
600MG · TABLET · BRISTOL-MYERS SQUIBB CANADA
DIN 02246045
Resolved
JAMP-EFAVIRENZ
600MG · TABLET · JAMP PHARMA CORPORATION
DIN 02458233 · ended Jul 19, 2022 · Disruption of the manufacture of the drug.
Resolved
SUSTIVA 50MG
50MG · CAPSULE · BRISTOL-MYERS SQUIBB CANADA
DIN 02239886 · ended Dec 10, 2020 · Delay in shipping of the drug.
Resolved
TEVA-EFAVIRENZ
600MG · TABLET · TEVA CANADA LIMITED
DIN 02389762 · ended Jun 10, 2020 · Disruption of the manufacture of the drug.

Showing 12 of 13 reports. All reports are on file with Health Canada.

What's happening

Efavirenz is currently affected by an active shortage report filed with Health Canada by TEVA CANADA LIMITED.

The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.

If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.

Efavirenz is classified under “DIRECT ACTING ANTIVIRALS” (ATC J05AG).

Recent changes

Common questions

When will Efavirenz be back in stock in Canada?

Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.

Why is Efavirenz in shortage?

See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Related drugs (direct acting antivirals)

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.